Kymera Therapeutics Inc at TD Cowen Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Marc Frahm - Cowen Inc - Analyst : But maybe to start off with, Nello, you want to just kind of give a high-level overview, and maybe the key takeaways from your earnings update the other day, and some of the updates you provided on clinical programs there.

Question: Marc Frahm - Cowen Inc - Analyst : Okay, sorry to touch on some of those comments on 621. I think that's a question we feel that some is trying to figure out why that data is in June, because I think maybe there was a sense that you might be able to finish that trial a little bit faster, particularly given that you're going to start that AD trial this quarter. Can you maybe explain some of that? What follow-up do you need before you fully know a dose?

Question: Marc Frahm - Cowen Inc - Analyst : So obviously, if you start that AD trial a bit before June, that means you're starting it with maybe not all of that biomarker data fully analyzed. Is that accurate? And then what do you need to select a dose to go into the Phase 1b versus --?

Question: Marc Frahm - Cowen Inc - Analyst : Okay. And then as you get that all that biomarker data, can you walk through how you will evaluate dose and that you're seeing the type of PD activity you'd expect?

Question: Marc Frahm - Cowen Inc - Analyst : And where are those -- as you get some of those Th2 biomarker data, where's the thresholds where you say the biology is working like you would expect? And is there a threshold on the high end where you'd say maybe some of these hints pre-clinically that this mechanism might be slightly more potent than a dupilumab, or is that going to play out?

Question: Marc Frahm - Cowen Inc - Analyst : And what about when we get to late in the year, when we get to these 1b data?

Question: Marc Frahm - Cowen Inc - Analyst : Okay. I think that covered it. Anybody want anything else on phase one before we get to it? Okay. So now you've already kind of started to lay out that Phase 2 plan. Maybe it's more of a Jared question. You want to run through what you've disclosed there around trials and then we can get into some of them.

Question: Marc Frahm - Cowen Inc - Analyst : Well, I guess 1b (multiple speakers).

Question: Marc Frahm - Cowen Inc - Analyst : Maybe back to some of the preclinical data. What are the kinetics of pathway inhibition, of getting that degradation look like relative to when you use an antibody to hit this pathway? And should we think of -- should we truly think of day 14 with an antibody as the same as day 14 with a degrader?

Question: Marc Frahm - Cowen Inc - Analyst : You mentioned the biomarkers in that Phase 1b, but with the clinical endpoints. How will you interpret the clinical endpoints, given that it's not a placebo-controlled trial? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MARCH 05, 2025 / 2:10PM, KYMR.OQ - Kymera Therapeutics Inc at TD Cowen Healthcare Conference

Question: Marc Frahm - Cowen Inc - Analyst : How much will this Phase 1b really inform your Phase 2b trials? Because if this isn't going to read out until almost year-end and you're starting a Phase 2b before year-end, like is there really much opportunity for this to even inform it? Is that all driven by health volunteers?

Question: Marc Frahm - Cowen Inc - Analyst : Maybe, Jared, you want to describe the Phase 2bs that have been disclosed? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MARCH 05, 2025 / 2:10PM, KYMR.OQ - Kymera Therapeutics Inc at TD Cowen Healthcare Conference

Question: Marc Frahm - Cowen Inc - Analyst : And dupi does have a handful of different dosing paradigms across diseases, but both kind of chronic dose, sometimes there's also loading dose. How much of that type of stuff do you think you need to explore? And do you -- or is an oral molecule, the distribution is much more standard and you can just have -- likely end up with one dose across everybody?

Question: Marc Frahm - Cowen Inc - Analyst : And you've got a handful of different trials here starting up this year between -- what's the kind of disclosure strategy, or do you plan on informing the investment community when you have actually started dosing the Phase 1b, or is no news good news?

Question: Marc Frahm - Cowen Inc - Analyst : Maybe turning to another program that's about to enter the clinic, the TYK2. I think many in the investment community have kind of soured on that as a target. What do you think they're missing?

Question: Marc Frahm - Cowen Inc - Analyst : That's possible. You want to lay out the phase one and how quickly we might know that what Melo just described is playing out and starting to drive different clinical outcomes?

Question: Marc Frahm - Cowen Inc - Analyst : I mean, biologics in psoriasis have their own range?

Question: Marc Frahm - Cowen Inc - Analyst : Do you just need to be in that range or do you need to be at the top?

Question: Marc Frahm - Cowen Inc - Analyst : Unfortunately, that's all the time we have, so we're going to have to cut it off there. But thanks very much, Nello and Jared, for joining and everyone in the room.